Affinage

Showing ACTL6A — ARP4 is a alias.

ACTL6A

Actin-like protein 6A · UniProt O96019

Length
429 aa
Mass
47.5 kDa
Annotated
2026-06-09
40 papers in source corpus 26 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ACTL6A (BAF53a) is an actin-related subunit of ATP-dependent chromatin remodeling complexes (SWI/SNF/BAF, INO80, and Tip60-p400) that controls cell fate by modulating which genes these complexes can access, acting both to maintain progenitor/stem states and, when overexpressed, to drive oncogenic transcription (PMID:23395444, PMID:34687603). In progenitor and stem cells it restrains differentiation: it blocks SWI/SNF binding to differentiation-gene promoters such as KLF4 in epidermal progenitors (PMID:23395444), is an essential, cell-autonomous requirement for hematopoietic stem cell function (PMID:23018638), and cooperates with pluripotency factors Nanog, Sox2, and Oct3/4 through a Tip60-p400-dependent activity to sustain the undifferentiated state and cell survival (PMID:25802002, PMID:29070872). In cancer, increased ACTL6A is stoichiometrically incorporated into BAF complexes, where it enhances genome-wide opposition to Polycomb repression and enables co-dependent loading of BAF and TEAD-YAP complexes to activate squamous-cell-carcinoma gene programs (PMID:34687603); it also suppresses the cell-cycle inhibitor p21Cip1 in a p53-independent manner by occupying Sp1 and p53 response elements in its promoter (PMID:32616890, PMID:34689163). ACTL6A additionally functions as a co-activator of redox and growth programs—partnering with NRF2 and BACH1 to drive glutathione-biosynthesis genes (GCLC, GCLM) and thereby suppress ferroptosis (PMID:37443154, PMID:41059410), interacting with MYC and VPS72 to enhance MYC target promoter binding (PMID:36631007), and promoting cisplatin-DNA adduct repair via SWI/SNF (PMID:33408251)—and is itself targeted for ubiquitin-dependent degradation by FBXW7 (PMID:36159747). Loss-of-function studies across glioblastoma, Schwann cells, and zebrafish further implicate ACTL6A in DNA replication initiation, myelination transcriptional programs, and ciliogenesis, in each case through chromatin-level control of lineage regulators [PMID:35182941, PMID:35434551, PMID:bio_10.1101_2025.06.10.658863].

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2012 High

    Established that ACTL6A is not merely a passive structural subunit but is functionally essential for an adult stem cell compartment in vivo, answering whether its BAF-complex role has organism-level consequences.

    Evidence Conditional knockout mouse with hematopoietic chimeras and bone marrow transplantation

    PMID:23018638

    Open questions at the time
    • Did not resolve which specific target genes mediate HSC failure
    • Did not separate BAF-specific from INO80/Tip60 contributions
  2. 2013 High

    Defined a mechanistic model in which ACTL6A actively gates SWI/SNF access to differentiation promoters, explaining how it maintains progenitor identity rather than simply enabling remodeling.

    Evidence Conditional knockout, ChIP, and ectopic expression in epidermal progenitors

    PMID:23395444

    Open questions at the time
    • Did not establish how ACTL6A is itself regulated to release this block during normal differentiation
    • Targets beyond KLF4 only partially mapped
  3. 2015 High

    Connected ACTL6A to the pluripotency transcription factor network and assigned the activity to a specific complex, showing it works through Tip60-p400 rather than BAF alone in ESCs.

    Evidence Co-IP, ChIP, RNAi, and Tip60/p400-binding domain-mutant rescue in mouse ESCs

    PMID:25802002

    Open questions at the time
    • Did not quantify partitioning of ACTL6A among BAF, INO80, and Tip60-p400 in ESCs
    • Direct versus indirect promoter effects not fully separated
  4. 2018 Medium

    Placed ACTL6A downstream of cellular energy and oxygen sensing, linking metabolic state to chromatin acetylation and pluripotency.

    Evidence Knockdown with ATP supplementation/rotenone (PMID 29222327) and sequential HIF-1α/Actl6a knockdown with H3K9ac readout (PMID 32112486) in ESCs/hiPSCs

    PMID:29222327 PMID:32112486

    Open questions at the time
    • Mechanism linking ATP/HIF-1α to ACTL6A expression not defined
    • Whether ACTL6A directly enables acetyltransferase activity not shown
  5. 2021 High

    Provided the quantitative basis for ACTL6A oncogenicity by showing dose-dependent stoichiometric assembly into BAF complexes drives Polycomb opposition and co-recruits TEAD-YAP, distinguishing tumor from normal function.

    Evidence ATAC-seq, ChIP-seq, CUT&RUN, and quantitative proteomics of BAF composition in SCCs

    PMID:34687603

    Open questions at the time
    • Mechanism of co-dependent BAF/TEAD-YAP loading not structurally resolved
    • Did not address whether the same applies outside squamous lineages
  6. 2020 Medium

    Identified p21Cip1 suppression as a concrete, p53-independent route by which ACTL6A enforces a proliferative cancer phenotype, naming the promoter elements engaged.

    Evidence ChIP, luciferase reporter, knockdown/rescue in SCC (PMID 32616890) and knockout with in vivo tumor assay in mesothelioma (PMID 34689163)

    PMID:32616890 PMID:34689163

    Open questions at the time
    • How ACTL6A is recruited to Sp1/p53 elements not defined
    • Whether repression is BAF-dependent not directly tested
  7. 2021 High

    Extended ACTL6A function from transcription into the DNA damage response, showing it promotes platinum-adduct repair through SWI/SNF and underlies chemoresistance.

    Evidence Overexpression/knockdown, cisplatin-DNA adduct repair assays, xenografts, and HDAC inhibitor reversal

    PMID:33408251

    Open questions at the time
    • Direct repair-factor recruitment by ACTL6A not demonstrated
    • Link between HDAC inhibition reversal and chromatin state mechanistic only
  8. 2023 High

    Revealed a non-canonical co-transcription-factor role in redox metabolism, with ACTL6A partnering NRF2 to drive glutathione synthesis and suppress ferroptosis.

    Evidence Co-IP, ChIP, luciferase reporter, and ROS/GSH measurements in gastric cancer; hydrophobic-region requirement mapped

    PMID:37443154

    Open questions at the time
    • Whether this depends on a remodeling complex or is complex-independent unclear
    • Direct GCLC promoter binding by ACTL6A versus via NRF2 not separated
  9. 2023 Medium

    Defined ACTL6A as a co-activator that boosts MYC transcriptional output and stabilizes its partner VPS72 against degradation, broadening its oncogenic interactome beyond chromatin remodeling subunits.

    Evidence Co-IP, co-localization, ChIP for MYC occupancy, and in vivo ubiquitination assay in HCC

    PMID:36631007

    Open questions at the time
    • Stoichiometry and structure of the ACTL6A/VPS72/MYC complex unknown
    • Single-lab evidence without reciprocal validation
  10. 2022 Medium

    Positioned ACTL6A within a degradative regulatory loop, identifying FBXW7 as the E3 ligase that limits ACTL6A levels and thereby its cancer-stem-cell-promoting activity.

    Evidence Co-IP, in vivo ubiquitination assay, and ACTL6A-overexpression rescue in HCC cells

    PMID:36159747

    Open questions at the time
    • Degron site on ACTL6A not mapped
    • Whether FBXW7 regulation is signal-responsive not addressed
  11. 2022 Medium

    Demonstrated tissue-specific requirements for ACTL6A in differentiated cell programs, showing it evicts repressive histone marks to license myelination and that loss of ACTL6A independently impairs DNA replication initiation.

    Evidence Conditional KO with histone mark analysis in Schwann cells (PMID 35434551) and knockdown with replication and ATR-Chk1 assays in glioblastoma (PMID 35182941)

    PMID:35182941 PMID:35434551

    Open questions at the time
    • Which complex mediates myelination versus replication roles not resolved
    • Direct versus indirect regulation of MCM5/CMG genes not fully established
  12. 2025 Medium

    Resolved the chromatin logic of ACTL6A loss in cancer, showing depletion opens new accessible regions where KLF4 recruits SWI/SNF and INO80 to activate p53-pathway apoptotic genes, mirroring the progenitor-state model in a tumor context.

    Evidence Multi-omics (ATAC-seq, ChIP-seq, RNA-seq) with knockdown in colorectal cancer

    PMID:40877226

    Open questions at the time
    • Mechanism by which ACTL6A normally occludes these regions not defined
    • Generalizability across tumor types untested
  13. 2025 Medium

    Expanded the co-activator repertoire to additional transcription factors and pathways, linking ACTL6A to BACH1-driven glutathione metabolism, BAP18/PAF1-Wnt/β-catenin signaling, and ciliogenesis master regulators.

    Evidence Co-IP/ChIP-seq with GCLM rescue in ESCC (PMID 41059410), Co-IP/reporter in NSCLC (PMID 40818609), and zebrafish KO with mRNA rescue (PMID bio_10.1101_2025.06.10.658863, preprint)

    PMID:40818609 PMID:41059410 PMID:bio_10.1101_2025.06.10.658863

    Open questions at the time
    • Whether these reflect distinct complexes or a shared mechanism unclear
    • Direct binding versus recruitment by partners not always separated

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how ACTL6A is partitioned among its distinct complexes (BAF, INO80, Tip60-p400) and how this partitioning is set by cell state to switch between maintaining progenitor identity and driving the diverse oncogenic and metabolic programs attributed to it.
  • No structural model of ACTL6A within each complex in the corpus
  • No unified determinant of complex choice identified
  • Direct DNA/histone-binding contribution of ACTL6A itself not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0008092 cytoskeletal protein binding 3 GO:0003677 DNA binding 2
Localization
GO:0005634 nucleus 3 GO:0000228 nuclear chromosome 2
Pathway
R-HSA-4839726 Chromatin organization 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1266738 Developmental Biology 3 R-HSA-69306 DNA Replication 1 R-HSA-73894 DNA Repair 1
Partners
BACH1FBXW7MYCNANOGNFE2L2POU5F1SOX2VPS72
Complex memberships
INO80SWI/SNF (BAF)Tip60-p400 (NuA4)

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 ACTL6A (BAF53a) prevents SWI/SNF complex binding to promoters of KLF4 and other differentiation genes in epidermal progenitors, thereby suppressing differentiation; conditional loss leads to terminal differentiation and SWI/SNF-dependent induction of KLF4 targets Conditional knockout, ChIP, ectopic expression, gene expression analysis Cell Stem Cell High 23395444
2012 BAF53a/ACTL6A is an essential subunit of BAF chromatin remodeling complexes required for hematopoietic stem cell (HSC) function; conditional deletion causes multilineage bone marrow failure and HSC proliferative impairment in a cell-autonomous manner Conditional knockout mouse, hematopoietic chimeras, flow cytometry, bone marrow transplantation Blood High 23018638
2023 ACTL6A acts as a co-transcription factor with NRF2 to upregulate GCLC expression, increasing glutathione synthesis and reducing lipid ROS, thereby protecting gastric cancer cells against ferroptosis; the hydrophobic region of ACTL6A is required for this activity Co-immunoprecipitation, ChIP, luciferase reporter assay, ROS/GSH measurements, knockdown/overexpression Nature Communications High 37443154
2021 ACTL6A overexpression enhances repair of cisplatin-DNA adducts, conferring platinum resistance; this regulation is mediated through the SWI/SNF chromatin remodeling complex, and HDAC inhibitors can reverse the effect of ACTL6A overexpression on DNA damage repair Overexpression/knockdown, cisplatin-DNA adduct repair assays, xenograft mouse model, HDAC inhibitor treatment Proceedings of the National Academy of Sciences of the United States of America High 33408251
2021 In squamous cell carcinomas (SCCs), increased ACTL6A levels lead to its stoichiometric assembly into BAF complexes; elevated ACTL6A occupancy enhances polycomb opposition genome-wide and facilitates co-dependent loading of BAF and TEAD-YAP complexes on chromatin to activate SCC genes ATAC-seq, ChIP-seq, ectopic expression, CUT&RUN, quantitative proteomics of BAF complex composition Molecular Cell High 34687603
2015 Actl6a interacts with Nanog and Sox2 in mouse ESCs, promotes Nanog binding to pluripotency gene promoters (Oct4, Sox2), and targets promoters of PrE regulators (Sall4, Fgf4) to repress their expression; mutant Actl6a with impaired Tip60/p400 binding fails to block primitive endoderm differentiation, indicating dependence on the Tip60-p400 complex Co-immunoprecipitation, ChIP, RNAi knockdown, ectopic expression, domain-mutant rescue experiments Stem Cells High 25802002
2013 BAF53a/ACTL6A is a direct target of miR-206 in rhabdomyosarcoma; sustained BAF53a expression blocks myogenic differentiation, while its silencing promotes differentiation marker expression, reduces proliferation, and impairs anchorage-independent growth and tumor formation miR-206 re-expression, BAF53a silencing (siRNA/shRNA), differentiation assays, in vivo tumor growth Oncogene Medium 23728344
2017 Baf53a interacts with Oct3/4 in mouse ES cells; Baf53a-deficient ES cells show increased p53, p21, and cleaved Caspase 3 and undergo cell death; a Baf53a M3 mutant (E388A/R389A/R390A) fails to rescue cell death, and Baf53b can compensate for Baf53a loss in ES cell survival Co-immunoprecipitation, tetracycline-inducible conditional knockout, domain mutagenesis (M3 mutant), rescue by overexpression of Baf53a or Baf53b Scientific Reports Medium 29070872
2018 ACTL6A interacts with and co-localizes with Sox2 and p53 in acute promyelocytic leukemia cells; knockdown of ACTL6A promotes differentiation and decreases Sox2 and Notch1 levels; p53 activator CBL0137 decreases ACTL6A expression and promotes differentiation Co-immunoprecipitation, co-localization assays, siRNA knockdown, pharmacological p53 activation Cellular Signalling Medium 30448346
2018 Mitochondrially produced ATP promotes Actl6a expression and histone acetylation; Actl6a knockdown reduces histone acetylation and pluripotency of ESCs, and this reduction cannot be rescued by exogenous ATP, placing Actl6a downstream of ATP in regulating pluripotency-associated histone acetylation Actl6a knockdown in ESCs, ATP supplementation, rotenone treatment, histone acetylation measurement FASEB Journal Medium 29222327
2020 HIF-1α knockdown inhibits Actl6a expression and H3K9 acetylation in hiPSCs; Actl6a knockdown in turn reduces H3K9ac and pluripotency, placing Actl6a downstream of HIF-1α in regulating histone acetylation and pluripotency maintenance shRNA knockdown of HIF-1α and Actl6a, histone acetylation measurement, EB and teratoma formation assays FASEB Journal Medium 32112486
2020 Long non-coding RNA uc.291 physically interacts with ACTL6A and modulates chromatin remodeling; upon uc.291 depletion, ACTL6A binds to promoters of differentiation genes and inhibits BAF complex targeting; presence of uc.291 releases the ACTL6A inhibitory effect to allow expression of terminal differentiation genes RNA immunoprecipitation, ChIP, knockdown of uc.291 in primary keratinocytes and 3D skin equivalents EMBO Reports Medium 32017402
2020 ACTL6A interacts with p53 DNA response elements and Sp1 binding sites in the p21Cip1 gene promoter to suppress p21Cip1 promoter activity, mRNA, and protein levels in epidermal SCC cells; increased p21Cip1 in ACTL6A knockdown cells is required for suppression of the SCC phenotype, and this regulation is p53-independent ChIP, luciferase reporter assay, siRNA knockdown, rescue experiments Oncogene Medium 32616890
2021 ACTL6A suppresses p21Cip1 expression by interacting with Sp1 and p53 binding elements in the p21Cip1 promoter in mesothelioma cells; ACTL6A knockout reduces tumor formation with elevated p21Cip1 in vivo ChIP, luciferase reporter assay, ACTL6A knockout, in vivo tumor formation Oncogenesis Medium 34689163
2022 ACTL6A knockdown impairs DNA replication initiation in glioblastoma cells by downregulating genes of the CDC45-MCM-GINS (CMG) complex; specifically, ACTL6A transcriptionally regulates MCM5 expression; ACTL6A knockdown also diminishes ATR-Chk1 pathway activity, leading to apoptosis siRNA knockdown, DNA replication assays, gene expression analysis, Western blot for ATR-Chk1 pathway components Biochemical and Biophysical Research Communications Medium 35182941
2022 ACTL6A (BAF53A) interacts with p63 in colorectal cancer cells; this interaction decreases DUSP5 expression, leading to increased ERK1/2 phosphorylation and enhanced cancer cell proliferation Co-immunoprecipitation, gene expression analysis, siRNA knockdown, Western blot for ERK1/2 phosphorylation Cell Death & Disease Medium 36526622
2023 ACTL6A interacts with MYC and VPS72; the ACTL6A/VPS72/MYC complex enhances MYC affinity for target gene promoters to promote transcription; ACTL6A also protects VPS72 from TRIM21-mediated ubiquitination and degradation Co-immunoprecipitation, protein co-localization, in vivo ubiquitination assay, ChIP Hepatology Medium 36631007
2022 FBXW7 binds ACTL6A and promotes its ubiquitin-dependent degradation; FBXW7 overexpression reduces cancer stem cell-like properties and tumorigenicity of HCC cells, and ACTL6A overexpression reverses these effects, placing ACTL6A as a downstream oncogenic target of FBXW7 Co-immunoprecipitation, protein co-localization, in vivo ubiquitination assay, rescue experiments with ACTL6A overexpression Stem Cells International Medium 36159747
2022 In Schwann cells, nuclear levels of ACTL6A are increased by contact with large-caliber axons or nanofibers; ACTL6A is required to evict repressive histone marks and facilitate myelination transcriptional programs; loss of Actl6a in conditional knockout mice causes defective radial sorting, hypo-myelination of large axons, and redundant myelin around small axons Conditional knockout mouse, live imaging, histone mark analysis, nanofiber contact assay iScience Medium 35434551
2025 ACTL6A depletion in colorectal cancer enhances KLF4 binding at newly accessible chromatin regions, where KLF4 cooperates with SWI/SNF and INO80 complexes to activate p53 pathway-related genes and induce apoptosis; multi-omics analysis shows ACTL6A deficiency alters chromatin accessibility genome-wide ATAC-seq, ChIP-seq, RNA-seq (multi-omics), ACTL6A knockdown Cell Death & Disease Medium 40877226
2025 BAF53A (ACTL6A) collaborates with BACH1 to transcriptionally activate GCLM (glutamate-cysteine ligase modifier subunit) in esophageal squamous cell carcinoma; this BAF53A-BACH1-GCLM axis maintains glutathione metabolism and ferroptosis resistance; GCLM overexpression rescues redox balance in BAF53A- or BACH1-silenced cells Co-immunoprecipitation, ChIP-seq, shRNA knockdown, rescue by GCLM overexpression, GSH/GSSG and ROS measurement PeerJ Medium 41059410
2025 BAP18 recruits ACTL6A and PAF1 to Wnt target gene promoters, enhancing β-catenin-mediated transcription in NSCLC; co-immunoprecipitation confirmed the BAP18-ACTL6A-PAF1 interaction Co-immunoprecipitation, luciferase reporter assay, RNA-seq, knockdown experiments Journal of Biological Chemistry Medium 40818609
2025 Loss of Actl6a in zebrafish leads to cilia disassembly and cystic kidney by downregulating master ciliogenesis regulators foxj1a and rfx2 at the transcriptional, chromatin accessibility, and SWI/SNF binding levels; overexpression of foxj1a or rfx2 mRNA partially rescues the cystic kidney and cilia disassembly phenotypes in actl6a mutants Zebrafish genetic knockout, ATAC-seq, ChIP-seq, mRNA rescue experiments, omics analyses bioRxiv (preprint)preprint Medium bio_10.1101_2025.06.10.658863
2019 ACTL6A positively regulates PGK1 expression in ovarian cancer; enforced ACTL6A expression increases PGK1 while knockdown decreases it; ACTL6A regulates FSH-enhanced glycolysis via PI3K/AKT pathway signaling upstream of ACTL6A Overexpression/knockdown, in vivo xenograft, qRT-PCR/Western blot, correlation in patient tissues Cell Death & Disease Low 31649264
2025 ACTL6A knockdown in HNSCC reduces aerobic glycolysis (Warburg effect) and blunts HIF1α/HIF2α protein induction under hypoxia; ACTL6A mediates chromatin accessibility at AP-1 transcription factor sites and regulates upstream MAPK signaling through induction of Ras and Galectin-1 ATAC-seq, Seahorse metabolic assay, shRNA knockdown, in vivo IACS-010759 treatment, Western blot bioRxiv (preprint)preprint Low 40950224
2025 Actl6a interacts with Sox2 in spinal cord neurons and collaboratively upregulates Atg5 and Atg7 expression to promote autophagy; Fto demethylase modulates Actl6a mRNA stability via m6A demethylation, placing Fto upstream of Actl6a in this pathway Co-immunoprecipitation, RNA immunoprecipitation (RIP), m6A dot blot, overexpression/knockdown, rat SCI model with AAV delivery Journal of Advanced Research Low 39875055

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 ACTL6a enforces the epidermal progenitor state by suppressing SWI/SNF-dependent induction of KLF4. Cell stem cell 102 23395444
2012 The BAF53a subunit of SWI/SNF-like BAF complexes is essential for hemopoietic stem cell function. Blood 102 23018638
2023 ACTL6A protects gastric cancer cells against ferroptosis through induction of glutathione synthesis. Nature communications 93 37443154
2021 ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer. Proceedings of the National Academy of Sciences of the United States of America 68 33408251
2013 Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma. Oncogene 50 23728344
2019 ACTL6A regulates follicle-stimulating hormone-driven glycolysis in ovarian cancer cells via PGK1. Cell death & disease 44 31649264
2015 Actl6a protects embryonic stem cells from differentiating into primitive endoderm. Stem cells (Dayton, Ohio) 44 25802002
2018 ACTL6A expression promotes invasion, metastasis and epithelial mesenchymal transition of colon cancer. BMC cancer 40 30348114
2021 Increased ACTL6A occupancy within mSWI/SNF chromatin remodelers drives human squamous cell carcinoma. Molecular cell 36 34687603
2020 Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex. EMBO reports 36 32017402
2020 MiR-216a-3p suppresses the proliferation and invasion of cervical cancer through downregulation of ACTL6A-mediated YAP signaling. Journal of cellular physiology 28 32401366
2017 Heterozygous variants in ACTL6A, encoding a component of the BAF complex, are associated with intellectual disability. Human mutation 27 28649782
2023 Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression. Hepatology (Baltimore, Md.) 25 36631007
2020 ACTL6A suppresses p21Cip1 expression to enhance the epidermal squamous cell carcinoma phenotype. Oncogene 25 32616890
2020 HIF-1α/Actl6a/H3K9ac axis is critical for pluripotency and lineage differentiation of human induced pluripotent stem cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 21 32112486
2022 BAF53A drives colorectal cancer development by regulating DUSP5-mediated ERK phosphorylation. Cell death & disease 19 36526622
2018 Mitochondrially produced ATP affects stem cell pluripotency via Actl6a-mediated histone acetylation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 19 29222327
2018 ACTL6A interacts with p53 in acute promyelocytic leukemia cell lines to affect differentiation via the Sox2/Notch1 signaling pathway. Cellular signalling 18 30448346
2017 Baf53a is involved in survival of mouse ES cells, which can be compensated by Baf53b. Scientific reports 18 29070872
2022 FBXW7 Reduces the Cancer Stem Cell-Like Properties of Hepatocellular Carcinoma by Regulating the Ubiquitination and Degradation of ACTL6A. Stem cells international 11 36159747
2022 ACTL6A deficiency induces apoptosis through impairing DNA replication and inhibiting the ATR-Chk1 signaling in glioblastoma cells. Biochemical and biophysical research communications 10 35182941
2021 ACTL6A promotes the growth in non-small cell lung cancer by regulating Hippo/Yap pathway. Experimental lung research 9 33896314
2021 ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes. OncoTargets and therapy 8 33469301
2022 ACTL6a coordinates axonal caliber recognition and myelination in the peripheral nerve. iScience 7 35434551
2020 ACTL6A knockdown inhibits cell migration by suppressing the AKT signaling pathway and enhances the sensitivity of glioma cells to temozolomide. Experimental and therapeutic medicine 7 33456542
2021 MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 6 34181232
2024 Sulforaphane suppresses cell proliferation and induces apoptosis in glioma via the ACTL6A/PGK1 axis. Toxicology mechanisms and methods 5 38221767
2020 The p.Arg377Trp variant in ACTL6A underlines a recognizable BAF-opathy phenotype. Clinical genetics 5 31994175
2021 ACTL6A suppresses p21Cip1 tumor suppressor expression to maintain an aggressive mesothelioma cancer cell phenotype. Oncogenesis 4 34689163
2025 Actl6a regulates autophagy via Sox2-dependent Atg5 and Atg7 expression to inhibit apoptosis in spinal cord injury. Journal of advanced research 3 39875055
2025 A multimodal approach for establishing ACTL6A and ERCC1 as chemoresistance genes in locally advanced head and neck cancer. Frontiers in pharmacology 1 40510426
2025 ACTL6A depletion induces KLF4-mediated anti-tumorigenic effects in colorectal cancer. Cell death & disease 1 40877226
2021 Case Report: BAF-Opathies/SSRIDDs Due to a de novo ACTL6A Variant, Previously Considered to Be Heart-Hand Syndrome. Frontiers in cardiovascular medicine 1 34485408
2025 Unveiling the role of ACTL6A in uveal melanoma metastasis and immune microenvironment. International immunopharmacology 0 39746274
2025 Emerging Roles of ACTL6A as an Oncogenic Hub: Transcriptional Regulation and Beyond. Molecular cancer research : MCR 0 40192597
2025 The chromatin remodeling factor BAP18 promotes non-small cell lung cancer progression via the recruitment of β-catenin with the transcriptional coactivator complex ACTL6A-PAF1. The Journal of biological chemistry 0 40818609
2025 ACTL6A regulates the Warburg effect through coordinated activation of AP-1 signaling in head and neck squamous cell carcinoma. bioRxiv : the preprint server for biology 0 40950224
2025 The BAF53A-BACH1-GCLM axis regulates glutathione metabolism and enhances ferroptosis resistance in esophageal squamous cell carcinoma. PeerJ 0 41059410
2025 The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β-Catenin Signaling Pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0 41137713
2025 ACTL6A accelerates the progression of NSCLC through hippo/YAP signaling axis and TAMs-mediated immune regulation. International immunopharmacology 0 41223612

Missed literature

Know a paper Affinage missed for ACTL6A? Flag it for the maintainers and the community.

No submissions yet.